Intellia Therapeutics Investors Alerted: Class Action Deadline Soon
The Gross Law Firm is notifying shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA) about an important class action lawsuit that affects those who purchased shares during a specific period. This notice is aimed at ensuring that all affected parties are aware of their rights and the next steps they can take.
Details on the Class Period
Shareholders who acquired shares of NTLA from July 30, 2024, to January 8, 2025, should pay attention to the upcoming legal proceedings. It is crucial for these investors to understand that taking part in this lawsuit could potentially lead to a recovery for losses sustained during this timeframe.
Key Allegations Against Intellia
The legal complaint outlines serious allegations concerning Intellia's Phase 1/2 study relating to NTLA-3001, which is positioned to treat the alpha-1 antitrypsin deficiency (AATD)-associated lung disease. According to the complaint, Intellia's leadership made claims regarding their commitment and excitement surrounding this study, projecting that the first patient would be dosed in the latter part of 2024.
However, the lawsuit indicates that behind closed doors, significant challenges were surfacing. Demand for viral-based gene editing was reportedly declining as the industry began shifting towards non-viral methods, which are considered more cost-effective and quicker to develop. This changing landscape made the continuation of NTLA-3001 increasingly unreasonable.
The Truth Comes to Light
On January 9, 2025, the situation became clearer when Intellia announced a major reorganization. In this release, it was disclosed that all research and development relating to NTLA-3001 would be halted and that the company would be reducing its workforce by 27%. This pivotal announcement significantly affected investor confidence, causing the market price of Intellia's shares to drop from $12.02 on January 8, 2025, to $10.20 by January 10, 2025.
Important Deadlines for shareholders
The deadline for shareholders to register for the class action lawsuit is April 14, 2025. Investors are advised not to postpone the registration process as it could impact their ability to participate in any potential recovery.
Next Steps for Interested Shareholders
Once investors register, they will be integrated into a portfolio monitoring system to keep them updated on the lawsuit's status. It is significant to note that aspiring lead plaintiffs must also register by April 14, 2025, and that participation in the suit incurs no costs or obligations.
Why Choose the Gross Law Firm?
The Gross Law Firm stands out as an experienced class action law firm focused on representing investors who may have suffered losses due to misinformation, fraud, or unethical corporate practices. Their dedication is evident in their mission to hold companies accountable and to promote fair business conduct.
Contact Information
For any inquiries or concerns, investors can reach out to:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the purpose of the class action lawsuit?
The class action lawsuit aims to consolidate claims from shareholders who experienced losses due to the company's alleged deceptive practices.
How can I register for the class action?
Investors can register by contacting the Gross Law Firm or visiting their website for more information and a submission form.
Is there a cost associated with participating?
No, participating in the class action lawsuit does not require any fees or financial commitment from the shareholders.
What if I purchased shares before July 30, 2024?
Only shareholders who purchased during the specified class period may participate in this class action lawsuit.
What should I do if I have more questions?
Interested shareholders should reach out to the Gross Law Firm for further clarification and assistance regarding their rights and the action.
